ReviewJournal of ovarian research2026
Insulin-like growth factor 1 as a key paracrine mediator in mesenchymal stem cell-based intervention for ovarian ageing: a review.
Review in Journal of ovarian research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundOvarian ageing refers to the progressive functional decline and structural degeneration of the ovary with advancing age, primarily manifested as a reduction in both the quantity and quality of follicles. These changes lead to decreased female fertility, increased miscarriage rates, and elevated risks of age-related diseases. Current treatments cannot fundamentally promote ovarian regeneration. Mesenchymal stem cells (MSCs) possess properties such as self-renewal and paracrine signalling, and their transplantation can restore ovarian function, with the paracrine pathway being a key mechanism. Insulin-like growth factor 1 (IGF-1), a peptide growth factor secreted by MSCs, regulates ovarian cell proliferation, differentiation, and survival through pathways like PI3K/Akt and Ras/Raf/MEK/ERK.
objectiveTo summarize and critically evaluate the latest research progress on the role of MSC-secreted IGF-1 in restoring ovarian function.
conclusionIGF-1 is an important mediator through which MSCs ameliorate ovarian ageing, improving ovarian tissue structure, hormone secretion, and fertility in preclinical models. However, most evidence remains preclinical, and future work should address the translational challenges, including safety, efficacy, and the precise role of IGF-1 within the complex MSCs paracrine network.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.